+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epilepsy Drugs Market, Global Forecast, Impact of COVID-19, Industry Trends, by Drugs Category, Growth, Opportunity Company Analysis

  • ID: 5411843
  • Report
  • August 2021
  • Region: Global
  • 120 pages
  • Renub Research
The Epilepsy Drugs Market is Projected to Reach US 10.3 Billion by 2027

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • GW Pharmaceuticals Plc.
  • H. Lundbeck A/S
  • UCB Inc.
  • MORE
Globally, millions of people are affected by neurological disorders. In that, over 80% of the death takes place in the low and middle-income countries. Worldwide Epilepsy is the most common neurological disorder, affecting people of all ages. This disease is a chronic brain disorder characterized by sudden and recurrent episodes of seizure. Patients who have epilepsy suffer from sudden behavioral changes, loss of consciousness and severe emotional distress. According to the World Health Organization (WHO), around 50 million people have epilepsy worldwide. Epilepsy is a common serious, and about 2.4 million new cases are diagnosed annually.



Besides, the rising incidence of higher birth-related injuries, neurological disorders, increasing road traffic injuries, growing disease awareness, and rising patient base in developing countries are the significant factors driving the global Epilepsy drug market. Increasing R&D investment and the launch of extended-release formulations are further expected to fuel the market growth. According to the publisher, the Global Epilepsy Drugs Market is projected to reach US$ 10.3 Billion by 2027.

Globally, United States is the largest epilepsy drug market due to better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after stroke, migraine, and Alzheimer’s disease. About one percent of Americans have some form of epilepsy, and nearly four percent (which is equal to 1 in 26) will develop epilepsy at some point in their lives. Thus, there is a rising demand for effective treatment in the US, significantly boosting the growth of the epilepsy drug market.

Additionally, China, India, and Brazil were among the countries with a higher proportion of the population suffering from the condition. To minimize the burden of this disease and facilitate the availability of better treatment options, governments from various countries across the world are providing active support. According to this research report, the Global Epilepsy Drugs Industry is likely to grow at a CAGR of 5.46% during (2020- 2027).

Based on Drugs Category

The global epilepsy drugs market is segmented into First Generation, Second Generation, Third Generation, Others. The third Generation holds the largest market share; the major factors responsible for the growth of the third generation segment include the launch of highly efficacy drugs with the enhanced mechanism of action, fewer side effects and the awaited launch of new pipeline medicines. Third-generation drugs such as Vimpat, Briviact and others have penetrated the worldwide market considerably and proven to be quite effective in treating epilepsy.

On the other hand, the second-generation antiepileptic drug class, including Keppra, Fycompa and Briviact. They dominated the market due to their large tolerability and safety due to the launch of highly potent drugs, which apply novel techniques mechanisms of action. Worldwide Epilepsy Drugs Market Size was US$ 7.1 Billion in 2020.

Top players such as Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, and GW Pharmaceuticals Plc. of Epilepsy Drugs Market focus on introducing medications that have lesser side-effects to the patients. Besides, companies are also focused on improving the potentiality of the drugs to control the symptoms of epilepsy effectively. In 2020, Eisai Co., Ltd. announced the launch of FYCOMPA in China to treat patients aged 12 years and more adults with partial-onset seizures.

This latest report “Global Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan) by Drugs Category (First Generation, Second Generation, Third Generation and Others) by Drugs (Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089) and Others) Company Analysis (Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.)” Provides a detailed analysis Global Epilepsy Drugs Industry.

Country - Global Epilepsy Drugs Market have been covered from 9 Viewpoints:

1. United States
2. United Kingdom
3. France
4. Germany
5. Italy
6. Spain
7. India
8. China
9. Japan

Drugs Category - Global Epilepsy Drugs Market have been covered from 4 Viewpoints:

1. First Generation
2. Second Generation
3. Third Generation
4. Others

Drugs - Global Epilepsy Drugs Market have been covered from 9 Viewpoints:

1. Vimpat (Lacosamide)
2. Keppra (Levetiracetam)
3. Sabril (Vigabatrin)
4. Onfi (Clobazam)
5. Fycompa
6. Briviact (Brivaracetam)
7. Epidiolex
8. Cenobamate (YKP3089)
9. Others

Company Insights:

  • Overview
  • Company Initiatives
  • Sales Analysis

Companies Covered:

1. Eisai Co., Ltd.
2. UCB Inc.
3. H. Lundbeck A/S
4. GW Pharmaceuticals Plc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • GW Pharmaceuticals Plc.
  • H. Lundbeck A/S
  • UCB Inc.
  • MORE
1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Global Epilepsy Drugs Market

6. Market Share - Global Epilepsy Drugs
6.1 By Country
6.2 By Drugs Category
6.3 By Drugs

7. Country - Global Epilepsy Drugs Market Analysis
7.1 United States
7.2 United Kingdom
7.3 France
7.4 Germany
7.5 Italy
7.6 Spain
7.7 India
7.8 China
7.9 Japan

8. Drugs Category - Global Epilepsy Drugs Market Analysis
8.1 First Generation
8.2 Second Generation
8.3 Third Generation
8.4 Others

9. Drugs - Global Epilepsy Drugs Market Analysis
9.1 Vimpat (Lacosamide)
9.2 Keppra (Levetiracetam)
9.3 Sabril (Vigabatrin)
9.4 Onfi (Clobazam)
9.5 Fycompa
9.6 Briviact (Brivaracetam)
9.7 Epidiolex
9.8 Cenobamate (YKP3089)
9.9 Others

10. Company Analysis
10.1 Eisai Co., Ltd.
10.1.1 Overview
10.1.2 Recent Development
10.1.3 Sales Analysis
10.2 UCB Inc.
10.2.1 Overview
10.2.2 Recent Development
10.2.3 Sales Analysis
10.3 H. Lundbeck A/S
10.3.1 Overview
10.3.2 Recent Development
10.3.3 Sales Analysis
10.4 GW Pharmaceuticals Plc.
10.4.1 Overview
10.4.2 Recent Development
10.4.3 Sales Analysis

List of Figure:
Figure-01: Global Epilepsy Drugs Market (Million US$), 2017 - 2020
Figure-02: Forecast for - Global Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-03: United States - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-04: United States - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-05: United Kingdom - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-06: United Kingdom - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-07: France - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-08: France - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-09: Germany - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-10: Germany - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-11: Italy - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-12: Italy - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-13: Spain - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-14: Spain - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-15: India - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-16: India - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-17: China - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-18: China - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-19: Japan - Epilepsy Drugs Market (Million US$), 2016 - 2020
Figure-20: Japan - Forecast for Epilepsy Drugs Market (Million US$), 2021 - 2027
Figure-21: Drugs Category - First Generation Market (Million US$), 2016 - 2020
Figure-22: Drugs Category - Forecast for First Generation Market (Million US$), 2021 - 2027
Figure-23: Drugs Category - Second Generation Market (Million US$), 2016 - 2020
Figure-24: Drugs Category - Forecast for Second Generation Market (Million US$), 2021 - 2027
Figure-25: Drugs Category - Third Generation Market (Million US$), 2016 - 2020
Figure-26: Drugs Category - Forecast for Third Generation Market (Million US$), 2021 - 2027
Figure-27: Drugs Category - Others Market (Million US$), 2016 - 2020
Figure-28: Drugs Category - Forecast for Others Market (Million US$), 2021 - 2027
Figure-29: Drugs - Vimpat (Lacosamide) Market (Million US$), 2016 - 2020
Figure-30: Drugs - Forecast for Vimpat (Lacosamide) Market (Million US$), 2021 - 2027
Figure-31: Drugs - Keppra (Levetiracetam) Market (Million US$), 2016 - 2020
Figure-32: Drugs - Forecast for Keppra (Levetiracetam) Market (Million US$), 2021 - 2027
Figure-33: Drugs - Sabril (Vigabatrin) Market (Million US$), 2016 - 2020
Figure-34: Drugs - Forecast for Sabril (Vigabatrin) Market (Million US$), 2021 - 2027
Figure-35: Drugs - Onfi (Clobazam) Market (Million US$), 2016 - 2020
Figure-36: Drugs - Forecast for Onfi (Clobazam) Market (Million US$), 2021 - 2027
Figure-37: Drugs - Fycompa Market (Million US$), 2016 - 2020
Figure-38: Drugs - Forecast for Fycompa Market (Million US$), 2021 - 2027
Figure-39: Drugs - Briviact (Brivaracetam) Market (Million US$), 2016 - 2020
Figure-40: Drugs - Forecast for Briviact (Brivaracetam) Market (Million US$), 2021 - 2027
Figure-41: Drugs - Epidiolex Market (Million US$), 2018 - 2020
Figure-42: Drugs - Forecast for Epidiolex Market (Million US$), 2021 - 2027
Figure-43: Drugs - Cenobamate (YKP3089) Market (Million US$), 2019 - 2020
Figure-44: Drugs - Forecast for Cenobamate (YKP3089) Market (Million US$), 2021 - 2027
Figure-45: Drugs - Others Market (Million US$), 2016 - 2020
Figure-46: Drugs - Forecast for Others Market (Million US$), 2021 - 2027

List of Tables:
Table-01: Global Epilepsy Drugs Market Share by Country (Percent), 2017 - 2020
Table-02: Forecast for - Global Epilepsy Drugs Market Share by Country (Percent), 2021 - 2027
Table-03: Global Epilepsy Drugs Market Share by Drugs Category (Percent), 2017 - 2020
Table-04: Forecast for - Global Epilepsy Drugs Market Share by Drugs Category (Percent), 2021 - 2027
Table-05: Global Epilepsy Drugs Market Share by Drugs (Percent), 2017 - 2020
Table-06: Forecast for - Global Epilepsy Drugs Market Share by Drugs (Percent), 2021 - 2027
Note: Product cover images may vary from those shown
  • Eisai Co., Ltd.
  • UCB Inc.
  • H. Lundbeck A/S
  • GW Pharmaceuticals Plc.
Note: Product cover images may vary from those shown

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll